%0 Journal Article %T Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer %A Tanaka, Satomi %A Uchino, Junji %J Translational Lung Cancer Research %D 2019 %B 2019 %9 %! Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer %K %X This Chinese randomized, open-label, phase 2 trial compared erlotinib with the standard-of-care vinorelbine plus cisplatin therapy as adjuvant treatment for patients with stage IIIA EGFR mutation-positive non-small cell lung cancer (NSCLC) who were able to undergo complete resection. %U https://tlcr.amegroups.org/article/view/29535 %P S369-S372 %@ 2226-4477